AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1907662 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia
Number of subjects: 161
Study 1907662 — intervention group
Group type: COMPARATOR
Intervention: Epidural morphine
Number of subjects: 161
Study 6138120 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimeprazine (sedative H1 antihistamine)
Number of subjects: 0
Study 6138120 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam (sedative benzodiazepine)
Number of subjects: 0
Study 6138120 — intervention group
Group type: COMPARATOR
Intervention: Astemizole (non-sedative H1 antihistamine)
Number of subjects: 0
Study 6138120 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine (non-sedative H1 antihistamine)
Number of subjects: 0
Study 30446849 — intervention group
Group type: EXPERIMENTAL
Intervention: MELD-Na score ≥ 10
Number of subjects: 48955
Study 30446849 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental increases in MELD-Na score (10–14)
Number of subjects: 48955
Study 30446849 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental increases in MELD-Na score (15–19)
Number of subjects: 48955
Study 30446849 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental increases in MELD-Na score (≥ 20)
Number of subjects: 48955
Study 28397649 — intervention group
Group type: EXPERIMENTAL
Intervention: New clinical protocol with referral pathway, training and support for paramedics.
Number of subjects: 2391
Study 28397649 — intervention group
Group type: COMPARATOR
Intervention: Control group continued practice as normal.
Number of subjects: 2391
Study 25637614 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed Osteopathic Manipulative Treatment (D-OMT)
Number of subjects: 0
Study 25637614 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondirected Osteopathic Manipulative Treatment (ND-OMT)
Number of subjects: 0
Study 25637614 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 0
Study 25637614 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (D-OMT, ND-OMT, Control)
Number of subjects: 0
Study 24212451 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention program including supervised physical activity, structured nutrition education, dietary modification, and behavioral support over 6 months.
Number of subjects: 145
Study 24212451 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention program
Number of subjects: 145
Study 24212451 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in energy intake
Number of subjects: 145
Study 24212451 — intervention group
Group type: COMPARATOR
Intervention: Physical activity
Number of subjects: 145
Study 22473616 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular stimulus presented before auditory stimulus (61 ms at 0.5 Hz, 19 ms at 1.0 Hz)
Number of subjects: 5
Study 21054847 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint Crisis Plan (JCP)
Number of subjects: 540
Study 21054847 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 540
Study 17931938 — intervention group
Group type: EXPERIMENTAL
Intervention: Proroot MTA mixed with water (group 1, n = 20)
Number of subjects: 44
Study 17931938 — intervention group
Group type: EXPERIMENTAL
Intervention: Proroot MTA without hydration (group 2, n = 20)
Number of subjects: 44
Study 15849222 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 0
Study 15849222 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy (with or without trastuzumab)
Number of subjects: 0
Study 12040975 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate for 2 months
Number of subjects: 86
Study 9620507 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA) - propofol, N2O, laryngeal mask airway
Number of subjects: 26
Study 9620507 — intervention group
Group type: COMPARATOR
Intervention: Epidural Anesthesia (EPID) - lidocaine 1.5% with epinephrine
Number of subjects: 26
Study 7703621 — intervention group
Group type: EXPERIMENTAL
Intervention: Ossein-hydroxyapatite (OHC)
Number of subjects: 40
Study 7703621 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate (CC)
Number of subjects: 40
Study 3080622 — intervention group
Group type: EXPERIMENTAL
Intervention: Unbalanced amino acid solutions (essential amino acids, branched‐chain amino acids)
Number of subjects: 0
Study 3080622 — intervention group
Group type: COMPARATOR
Intervention: Balanced and complete amino acid solution
Number of subjects: 0
Study 28177498 — intervention group
Group type: EXPERIMENTAL
Intervention: mTHS
Number of subjects: 160
Study 28177498 — intervention group
Group type: COMPARATOR
Intervention: mCC
Number of subjects: 160
Study 28177498 — intervention group
Group type: COMPARATOR
Intervention: SA
Number of subjects: 160
Study 27813452 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized cognitive remediation
Number of subjects: 420
Study 27813452 — intervention group
Group type: COMPARATOR
Intervention: Computer-based health education training
Number of subjects: 420
Study 25483701 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16/18 vaccine
Number of subjects: 0
Study 25483701 — intervention group
Group type: COMPARATOR
Intervention: HPV-6/11/16/18 vaccine
Number of subjects: 0
Study 22152673 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer Assessment of Simulated Patient Interviews (CASPI)
Number of subjects: 120
Study 20462091 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% phenylephrine
Number of subjects: 100
Study 20462091 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% phenylephrine
Number of subjects: 100
Study 20462091 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 100
Study 18664777 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP (5‐8 cm H2O)
Number of subjects: 131
Study 18664777 — intervention group
Group type: COMPARATOR
Intervention: Control (no PEEP)
Number of subjects: 131
Study 18389361 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexually active heterosexual men
Number of subjects: 290
Study 18389361 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexually active gay/bisexual men
Number of subjects: 290
Study 18389361 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexually active heterosexual women
Number of subjects: 290
Study 18389361 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sexual activity
Number of subjects: 290
Study 15179103 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity aerobic interval exercise (80-90% of VO2peak)
Number of subjects: 21
Study 15179103 — intervention group
Group type: COMPARATOR
Intervention: Moderate intensity exercise (50-60% of VO2peak)
Number of subjects: 21
Study 11740265 — intervention group
Group type: EXPERIMENTAL
Intervention: DPL-CT
Number of subjects: 252
Study 11740265 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 252
Study 9863123 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiaoxue Yisui recipe
Number of subjects: 78
Study 9863123 — intervention group
Group type: COMPARATOR
Intervention: SSL regimen
Number of subjects: 78
Study 8349939 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (40 mg)
Number of subjects: 20
Study 8349939 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide (2 mg)
Number of subjects: 20
Study 8349939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2882868 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 8
Study 2882868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31603024 — intervention group
Group type: EXPERIMENTAL
Intervention: Quick responding
Number of subjects: 1500
Study 31603024 — intervention group
Group type: COMPARATOR
Intervention: Slow responding
Number of subjects: 1500
Study 31603024 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast responding
Number of subjects: 1500
Study 28987287 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentially effective low-risk treatments for weight-loss devices
Number of subjects: 0
Study 28987287 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentially less effective and riskier treatments for weight-loss devices
Number of subjects: 0
Study 28987287 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal RCT design for weight-loss devices
Number of subjects: 0
Study 26781700 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-to-eat food product (Vita-Weat biscuit) as part of a diet prescription for weight loss
Number of subjects: 76
Study 26781700 — intervention group
Group type: COMPARATOR
Intervention: Advice on the 'Australian Guide to Healthy Eating' (control group)
Number of subjects: 76
Study 24552306 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified diagnostics (concentrated AFB smear and tuberculosis culture)
Number of subjects: 70
Study 24552306 — intervention group
Group type: COMPARATOR
Intervention: Standard diagnostics (direct AFB smear only)
Number of subjects: 70
Study 24552306 — intervention group
Group type: EXPERIMENTAL
Intervention: Antituberculosis therapy
Number of subjects: 70
Study 22367487 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline-supplemented diet (T(3))
Number of subjects: 270
Study 22367487 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaine-supplemented diet (T(4))
Number of subjects: 270
Study 22367487 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecithin-supplemented diet (T(5))
Number of subjects: 270
Study 22367487 — intervention group
Group type: COMPARATOR
Intervention: Control diet (T(0))
Number of subjects: 270
Study 22367487 — intervention group
Group type: COMPARATOR
Intervention: Control diet with endosulfan (T(1))
Number of subjects: 270
Study 22367487 — intervention group
Group type: COMPARATOR
Intervention: Control diet with endosulfan and elevated temperature (T(2))
Number of subjects: 270
Study 20869326 — intervention group
Group type: EXPERIMENTAL
Intervention: Total disc arthroplasty (TDA)
Number of subjects: 93
Study 20869326 — intervention group
Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion (ACDF)
Number of subjects: 93
Study 17998837 — intervention group
Group type: EXPERIMENTAL
Intervention: E. coli Nissle (Mutaflor)
Number of subjects: 39
Study 17998837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 15353421 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interviews
Number of subjects: 1270
Study 15353421 — intervention group
Group type: COMPARATOR
Intervention: Mailed questionnaires
Number of subjects: 1270
Study 15353421 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of telephone interviews
Number of subjects: 1270
Study 15353421 — intervention group
Group type: COMPARATOR
Intervention: Cost of mailed questionnaires
Number of subjects: 1270
Study 12439366 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam mesylate
Number of subjects: 0
Study 12439366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9855212 — intervention group
Group type: EXPERIMENTAL
Intervention: Distension combined with steroid
Number of subjects: 20
Study 9855212 — intervention group
Group type: COMPARATOR
Intervention: Steroid alone
Number of subjects: 20
Study 7989481 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative plasma prorenin and renin concentrations measured in children with nephroblastoma
Number of subjects: 25
Study 7989481 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in plasma prorenin concentration
Number of subjects: 25
Study 7989481 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephroblastoma tissue analysis
Number of subjects: 25
Study 2651106 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium acetate infusion at 2.5 mmoles/min for 60 min
Number of subjects: 12
Study 2651106 — intervention group
Group type: COMPARATOR
Intervention: Sodium bicarbonate infusion (control)
Number of subjects: 12
Study 29090685 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (8 mg/kg, 3 monthly infusions)
Number of subjects: 36
Study 29090685 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 36
Study 28463714 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stage integrated care (IC)
Number of subjects: 170
Study 28463714 — intervention group
Group type: COMPARATOR
Intervention: Antipsychotic medication-alone
Number of subjects: 170
Study 26323969 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma Delta Tocotrienol (GDT) - 2 capsules of 300 mg (450 mg γ‐T3 and 150 mg δ‐T3)
Number of subjects: 0
Study 26323969 — intervention group
Group type: COMPARATOR
Intervention: Tocotrienol-Rich Fraction (TRF) - 4 capsules of 200 mg (451.2 mg γ‐T3 & 102.72 mg δ‐T3)
Number of subjects: 0
Study 26323969 — intervention group
Group type: EXPERIMENTAL
Intervention: GDT and TRF
Number of subjects: 0
Study 24548399 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant tissue plasminogen activator (rt‐PA) and parental anticoagulant
Number of subjects: 90
Study 24548399 — intervention group
Group type: COMPARATOR
Intervention: parental anticoagulation
Number of subjects: 90
Study 22027736 — intervention group
Group type: EXPERIMENTAL
Intervention: DEB SeQuent Please
Number of subjects: 84
Study 22027736 — intervention group
Group type: COMPARATOR
Intervention: DES Taxus Liberté
Number of subjects: 84
Study 18303156 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (1 mg, 0.04 ml)
Number of subjects: 28
Study 18303156 — intervention group
Group type: COMPARATOR
Intervention: Photodynamic therapy (PDT) plus intravitreal triamcinolone (4 mg)
Number of subjects: 28
Study 16529689 — intervention group
Group type: EXPERIMENTAL
Intervention: Thread-dragging through fistula method
Number of subjects: 244
Study 16529689 — intervention group
Group type: COMPARATOR
Intervention: Control group (incision or thread-drawing)
Number of subjects: 244
Study 12419013 — intervention group
Group type: EXPERIMENTAL
Intervention: Anonymity of in-group members to the self
Number of subjects: 2
Study 12419013 — intervention group
Group type: EXPERIMENTAL
Intervention: Anonymity of the self to the group
Number of subjects: 2
Study 10352330 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF
Number of subjects: 132
Study 10352330 — intervention group
Group type: COMPARATOR
Intervention: Control (historical controls without G‐CSF)
Number of subjects: 132
Study 7856699 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 2947
Study 7856699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2947
Study 2044736 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 25 units
Number of subjects: 268
Study 2044736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 268
Study 6889432 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein diet
Number of subjects: 12
Study 6889432 — intervention group
Group type: COMPARATOR
Intervention: Animal protein diet
Number of subjects: 12
Study 30559151 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Number of subjects: 32
Study 28969711 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty fish meals three times per week for 12 weeks
Number of subjects: 426
Study 28969711 — intervention group
Group type: COMPARATOR
Intervention: Meat meals
Number of subjects: 426
Study 28969711 — intervention group
Group type: COMPARATOR
Intervention: n‐3 LCPUFA supplements
Number of subjects: 426
Study 25260247 — intervention group
Group type: COMPARATOR
Intervention: Continuous exercise (CE, 30‐min cycling)
Number of subjects: 16
Study 25260247 — intervention group
Group type: COMPARATOR
Intervention: Accumulated exercise with 20 min of interval (AE20, 2 × 15‐min cycling)
Number of subjects: 16
Study 25260247 — intervention group
Group type: COMPARATOR
Intervention: Accumulated exercise with 60 min of interval (AE60, 2 × 15‐min cycling)
Number of subjects: 16
Study 24519631 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% bupivacaine with 15 μg·mL(‐1) hydromorphone (LA group)
Number of subjects: 39
Study 24519631 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (NS group)
Number of subjects: 39
Study 22278302 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated e-mail-based alert system
Number of subjects: 121
Study 22278302 — intervention group
Group type: COMPARATOR
Intervention: Control group (no automated alerts)
Number of subjects: 121
Study 22278302 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient physician awareness
Number of subjects: 121
Study 22278302 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact on clinical assessments and plans
Number of subjects: 121
Study 22278302 — intervention group
Group type: EXPERIMENTAL
Intervention: Urgency of results
Number of subjects: 121
Study 22278302 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred alerting scenarios
Number of subjects: 121
Study 19254939 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle program intervention
Number of subjects: 460
Study 19254939 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 460
Study 17914545 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinutren HPR (whole protein of high protein value)
Number of subjects: 38
Study 17914545 — intervention group
Group type: EXPERIMENTAL
Intervention: Crucial (casein peptide based formula)
Number of subjects: 38
Study 17914545 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptamen (whey peptide based formula)
Number of subjects: 38
Study 17914545 — intervention group
Group type: EXPERIMENTAL
Intervention: Glytrol (formula for diabetics with whole protein with fiber)
Number of subjects: 38
Study 17914545 — intervention group
Group type: COMPARATOR
Intervention: Standard meal (bread)
Number of subjects: 38
Study 15284305 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin therapy
Number of subjects: 6800
Study 15284305 — intervention group
Group type: COMPARATOR
Intervention: Control (no digoxin therapy)
Number of subjects: 6800
Study 11448320 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT thickness at the 5‐o'clock inferior temporal position
Number of subjects: 91
Study 11448320 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT mean height contour in the nasal inferior region
Number of subjects: 91
Study 11448320 — intervention group
Group type: EXPERIMENTAL
Intervention: GDx linear discriminant function
Number of subjects: 91
Study 11448320 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative assessment of stereophotographs
Number of subjects: 91
Study 11448320 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT parameters
Number of subjects: 91
Study 11448320 — intervention group
Group type: EXPERIMENTAL
Intervention: GDx parameters
Number of subjects: 91
Study 11448320 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT parameters
Number of subjects: 91
Study 9212121 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.5 mg/kg
Number of subjects: 24
Study 9212121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8427134 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic shocks
Number of subjects: 12
Study 8427134 — intervention group
Group type: COMPARATOR
Intervention: Sequential pulse shocks
Number of subjects: 12
Study 3676051 — intervention group
Group type: EXPERIMENTAL
Intervention: Single breath induction technique with isoflurane in nitrous oxide and oxygen
Number of subjects: 36
Study 3676051 — intervention group
Group type: COMPARATOR
Intervention: Conventional inhalation induction technique with isoflurane in nitrous oxide and oxygen
Number of subjects: 36
Study 30299491 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 663
Study 28669167 — intervention group
Group type: EXPERIMENTAL
Intervention: AXL1717
Number of subjects: 0
Study 28669167 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 0
Study 28669167 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocytosis (WBC > 9 x 10^9/L)
Number of subjects: 0
Study 28669167 — intervention group
Group type: COMPARATOR
Intervention: Normal WBC (WBC ≤ 9 x 10^9/L)
Number of subjects: 0
Study 28669167 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia (Hgb < 110 g/L)
Number of subjects: 0
Study 28669167 — intervention group
Group type: COMPARATOR
Intervention: Normal Hgb (Hgb ≥ 110 g/L)
Number of subjects: 0
Study 28669167 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombocytosis (Plt > 350 x 10^9/L)
Number of subjects: 0
Study 28669167 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocytosis in multivariate model
Number of subjects: 0
Study 25837356 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin (group B)
Number of subjects: 138
Study 25837356 — intervention group
Group type: COMPARATOR
Intervention: Removing Stasis and Reducing Heat Formula (group C)
Number of subjects: 138
Study 25837356 — intervention group
Group type: COMPARATOR
Intervention: Control group (group A)
Number of subjects: 138
Study 24334483 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) with balance exercise
Number of subjects: 55
Study 24334483 — intervention group
Group type: COMPARATOR
Intervention: Balance exercise (BE)
Number of subjects: 55
Study 24334483 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 55
Study 20169458 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental solution (SnCl(2) with 1,900 ppm Sn(2+) and 1,000 ppm F(-), pH 4.5)
Number of subjects: 8
Study 20169458 — intervention group
Group type: COMPARATOR
Intervention: Positive control (SnF(2) mouth rinse with 409 ppm Sn(2+) and 250 ppm F(-), pH 4.2)
Number of subjects: 8
Study 20169458 — intervention group
Group type: COMPARATOR
Intervention: Placebo (negative control)
Number of subjects: 8
Study 19930833 — intervention group
Group type: EXPERIMENTAL
Intervention: Embolization of the draining veins with absolute ethanol followed by bleomycin A5 hydrochloride intra-tumoural injection
Number of subjects: 204
Study 19930833 — intervention group
Group type: COMPARATOR
Intervention: Intra-tumoural injection only
Number of subjects: 204
Study 16767966 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg dexamethasone intravenously before induction of anesthesia
Number of subjects: 700
Study 16767966 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% normal saline 2 ml)
Number of subjects: 700
Study 15564114 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy subjects (normal sleep stages)
Number of subjects: 12
Study 15564114 — intervention group
Group type: COMPARATOR
Intervention: Sleep apnea
Number of subjects: 12